Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

Diabetologia

Volumn 54, Issue 10, 2011, Pages 2669-2677

  Thomas, M C ^a,b   Soderlund J ^b,c   Lehto, M ^b   Makinen V P ^b   Moran, J L ^d   Cooper, M E ^a   Forsblom, C ^b,c   Groop, P H ^b,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Advanced glycation end products; AGE; Mortality; RAGE; Type 1 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

ADULT; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC;

EID: 80054109172     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2186-5     Document Type: Article

References (46)

1. A Goldin JA Beckman AM Schmidt MA Creager 2006 Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 597 605 16894049 10.1161/CIRCULATIONAHA.106.621854 1:CAS:528: DC%2BD28Xns1Snu70%3D (Pubitemid 44199649)
2. A Soro-Paavonen AM Watson J Li, et al. 2008 Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes Diabetes 57 2461 2469 18511846 10.2337/db07-1808 1:CAS:528:DC%2BD1cXhtFSrtrnP
3. LG Bucciarelli T Wendt W Qu, et al. 2002 RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice Circulation 106 2827 2835 12451010 10.1161/01.CIR.0000039325.03698.36 1:CAS:528: DC%2BD38XoslSnsLs%3D (Pubitemid 35396983)
4. TM Wendt N Tanji J Guo, et al. 2003 RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy Am J Pathol 162 1123 1137 12651605 10.1016/S0002-9440(10) 63909-0 1:CAS:528:DC%2BD3sXjtVemtL8%3D (Pubitemid 36350658)
5. L Zhang M Bukulin E Kojro, et al. 2008 Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases J Biol Chem 283 35507 35516 18952609 10.1074/jbc.M806948200 1:CAS:528: DC%2BD1cXhsVylsrrE
6. H Yonekura Y Yamamoto S Sakurai, et al. 2003 Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury Biochem J 370 1097 1109 12495433 10.1042/BJ20021371 1:CAS:528:DC%2BD3sXhvFKhsb0%3D (Pubitemid 36399105)
7. M Challier S Jacqueminet O Benabdesselam A Grimaldi JL Beaudeux 2005 Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes Clin Chem 51 1749 1750 16120960 10.1373/clinchem.2005.051961 1:CAS:528:DC%2BD2MXps1yku7o%3D (Pubitemid 41233122)
8. H Koyama T Shoji H Yokoyama, et al. 2005 Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis Arterioscler Thromb Vasc Biol 25 2587 2593 16224056 10.1161/01.ATV.0000190660.32863.cd 1:CAS:528:DC%2BD2MXht1Crt7rM (Pubitemid 43732283)
9. JM Forbes SR Thorpe V Thallas-Bonke, et al. 2005 Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy J Am Soc Nephrol 16 2363 2372 15930093 10.1681/ASN.2005010062 1:CAS:528:DC%2BD2MXovVOkurc%3D (Pubitemid 41725054)
10. T Gohda M Tanimoto JY Moon, et al. 2008 Increased serum endogenous secretory receptor for advanced glycation end-product (esRAGE) levels in type 2 diabetic patients with decreased renal function Diabetes Res Clin Pract 81 196 201 18550199 10.1016/j.diabres.2008.04.013 1:CAS:528:DC%2BD1cXptVKns7g%3D
11. RDFL Semba JC Fink K Sun, et al. 2009 Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women Am J Kidney Dis 53 51 58 18789567 10.1053/j.ajkd.2008. 06.018
12. Y Jang JY Kim SM Kang, et al. 2007 Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans Metabolism 56 199 205 17224333 10.1016/j.metabol.2006.09. 013 1:CAS:528:DC%2BD2sXlslSgtQ%3D%3D (Pubitemid 46074066)
13. M Kalousova M Jachymova O Mestek, et al. 2007 Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients Nephrol Dial Transplant 22 2020 2026 17347281 10.1093/ndt/gfm050 1:CAS:528:DC%2BD2sXos12ht7w%3D (Pubitemid 47244776)
14. M Catalano A Cortelazzo R Santi, et al. 2008 The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (receptor for advanced glycation endproducts) and the presence of peripheral arterial disease Clin Biochem 41 981 985 18538667 10.1016/j.clinbiochem.2008.05.007 1:CAS:528:DC%2BD1cXoslemt7g%3D
15. K Kankova M Kalousova M Hertlova D Krusova J Olsovsky T Zima 2008 Soluble RAGE, diabetic nephropathy and genetic variability in the AGER gene Arch Physiol Biochem 114 111 119 18615900 10.1080/13813450802033818 1:CAS:528:DC%2BD1cXotlKlsLc%3D (Pubitemid 351892711)
16. C Falcone E Emanuele A D'Angelo, et al. 2005 Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men Arterioscler Thromb Vasc Biol 25 1032 1037 15731496 10.1161/01.ATV.0000160342.20342.00 1:CAS:528:DC%2BD2MXjsVCjt7s%3D (Pubitemid 40627851)
17. JB Lindsey JA de Lemos F Cipollone, et al. 2009 Association between circulating soluble receptor for advanced glycation end products (sRAGE) and atherosclerosis: observations from the Dallas Heart Study Diabetes Care 32 1218 1220 19366975 10.2337/dc09-0053 1:CAS:528:DC%2BD1MXps1KqsL8%3D
18. M Saraheimo AM Teppo C Forsblom J Fagerudd PH Groop 2003 Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients Diabetologia 46 1402 1407 12928771 10.1007/s00125-003-1194-5 1:CAS:528:DC%2BD3sXnvVCgur8%3D (Pubitemid 37297211)
19. PH Groop MC Thomas JL Moran, et al. 2009 The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes Diabetes 58 1651 1658 19401416 10.2337/db08-1543 1:CAS:528:DC%2BD1MXos1Cqu7s%3D
20. VP Makinen C Forsblom LM Thorn, et al. 2008 Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes Diabetes 57 2480 2487 18544706 10.2337/db08-0332 1:CAS:528:DC%2BD1cXhtFSrtrnJ
21. AS Levey LA Stevens CH Schmid, et al. 2009 A new equation to estimate glomerular filtration rate Ann Intern Med 150 604 612 19414839
22. Force ICGT (2005) Global guideline for type 2 diabetes. International Diabetes Federation, Brussels
23. S Vandenplas I Wiid A Grobler-Rabie, et al. 1984 Blot hybridisation analysis of genomic DNA J Med Genet 21 164 172 6086927 10.1136/jmg.21.3.164 1:CAS:528:DyaL2cXls1Knt74%3D (Pubitemid 14119134)
24. SB Gabriel SF Schaffner H Nguyen, et al. 2002 The structure of haplotype blocks in the human genome Science 296 2225 2229 12029063 10.1126/science. 1069424 1:CAS:528:DC%2BD38XkvFGhtrc%3D (Pubitemid 34680308)
25. J Fine RJ Gray 1999 A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 496 509 10.2307/2670170
26. Pintilie M (2006) Competing risks: a practical perspective. Wiley, Chichester
27. GL Grunkemeier R Jin MJ Eijkemans JJ Takkenberg 2007 Actual and actuarial probabilities of competing risks: apples and lemons Ann Thorac Surg 83 1586 1592 17462363 10.1016/j.athoracsur.2006.11.044 (Pubitemid 46616757)
28. JM Forbes MC Thomas SR Thorpe NL Alderson ME Cooper 2004 The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes Kidney Int Suppl 92 S105 S107 15485399 10.1111/j.1523-1755.2004.09225.x 1:CAS:528:DC%2BD2cXhtVGgtL3J (Pubitemid 43361443)
29. P Royston 2006 Explained variation for survival models Stata J 6 83 96 (Pubitemid 43708445)
30. P Royston 2000 A strategy for modelling the effect of a continuous covariate in medicine and epidemiology Stat Med 19 1831 1847 10867674 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1 1:STN:280:DC%2BD3M%2FotlGitA%3D%3D (Pubitemid 30448192)
31. EL Barr PZ Zimmet TA Welborn, et al. 2007 Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Circulation 116 151 157 17576864 10.1161/ CIRCULATIONAHA.106.685628 1:CAS:528:DC%2BD2sXntlWqurg%3D (Pubitemid 47057520)
32. GD Smith N Timpson S Ebrahim 2008 Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization Ann Med 40 524 541 18608114 10.1080/07853890802010709
33. P Elliott JC Chambers W Zhang, et al. 2009 Genetic loci associated with C-reactive protein levels and risk of coronary heart disease JAMA 302 37 48 19567438 10.1001/jama.2009.954 1:CAS:528:DC%2BD1MXotFKns78%3D
34. FF Hou H Ren WF Owen Jr, et al. 2004 Enhanced expression of receptor for advanced glycation end products in chronic kidney disease J Am Soc Nephrol 15 1889 1896 15213278 10.1097/01.ASN.0000131526.99506.F7 1:CAS:528: DC%2BD2cXltVOjtbk%3D (Pubitemid 38822069)
35. JW Nin I Ferreira CG Schalkwijk, et al. 2009 Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study Diabetologia 52 705 714 19183936 10.1007/s00125-009-1263-5 1:STN:280:DC%2BD1M7mvFSksw%3D%3D
36. JW Nin A Jorsal I Ferreira, et al. 2010 Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study Diabetes 59 2027 2032 20522598 10.2337/db09-1509 1:CAS:528:DC%2BC3cXhtVOlsbjP
37. H Koyama T Shoji S Fukumoto, et al. 2007 Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease Arterioscler Thromb Vasc Biol 27 147 153 17082489 10.1161/01.ATV.0000251502.88818.4b 1:CAS:528:DC%2BD28XhtlSrsb7P (Pubitemid 46360392)
38. R Ramasamy SF Yan AM Schmidt 2009 RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts J Leukoc Biol 86 505 512 19477910 10.1189/jlb.0409230 1:CAS:528:DC%2BD1MXhtFahtLfJ
39. K Nakamura S Yamagishi H Adachi, et al. 2007 Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes Mol Med 13 185 189 17592553 10.2119/2006-00090.Nakamura 1:CAS:528:DC%2BD2sXotVOmt7o%3D (Pubitemid 46944961)
40. K Nakamura S Yamagishi H Adachi, et al. 2008 Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes Microvasc Res 76 52 56 18474381 10.1016/j.mvr.2007.09.004 1:CAS:528:DC%2BD1cXns1agsLk%3D
41. N Grossin MP Wautier T Meas PJ Guillausseau P Massin JL Wautier 2008 Severity of diabetic microvascular complications is associated with a low soluble RAGE level Diabetes Metab 34 392 395 18701333 10.1016/j.diabet.2008.04. 003 1:CAS:528:DC%2BD1cXhtlGitbzI
42. WD Comper B Haraldsson WM Deen 2008 Resolved: normal glomeruli filter nephrotic levels of albumin J Am Soc Nephrol 19 427 432 18216311 10.1681/ASN.2007090997 (Pubitemid 351355385)
43. K Borch-Johnsen PK Andersen T Deckert 1985 The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus Diabetologia 28 590 596 4054448 10.1007/BF00281993 1:STN:280:DyaL28%2FjtFSjtg%3D%3D (Pubitemid 15017393)
44. F Santilli L Bucciarelli D Noto, et al. 2007 Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins Free Radic Biol Med 43 1255 1262 17893038 10.1016/j.freeradbiomed.2007.06.017 1:CAS:528:DC%2BD2sXhtVOis7nF (Pubitemid 47429934)
45. D Geroldi C Falcone E Emanuele, et al. 2005 Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension J Hypertens 23 1725 1729 16093918 10.1097/01.hjh.0000177535.45785. 64 1:CAS:528:DC%2BD2MXnt1yku7w%3D (Pubitemid 41233433)
46. KJ Jager VS Stel C Wanner C Zoccali FW Dekker 2007 The valuable contribution of observational studies to nephrology Kidney Int 72 671 675 17597701 10.1038/sj.ki.5002397 1:STN:280:DC%2BD2sritVOhtw%3D%3D (Pubitemid 47373787)